Distribution of breast cancer patients with positive receptors according to HER2 and age
|
ER+PgR+
|
666
|
172
|
838
|
<55
|
218
|
69
|
287
|
ER+PgR−
|
66
|
38
|
104
|
>54
|
525
|
141
|
666
|
ER−PgR+
|
11
|
0
|
11
|
Total
|
743
|
210
|
953
|
Total
|
743
|
210
|
953
|
Χ2 (p)
|
13.70 (0.0002)
|
Χ2(p)
|
2.34 (0.1260)
|
Distribution of ductal breast cancer patients according to their steroid receptor phenotype and Ki-67 value
|
ER+ tumors without HER2
|
Luminal A (Ki-67 < =14%)
|
Luminal B1 (Ki-67 > 14%)
|
Total
|
Luminal B2
|
Ki-67 < =14%
|
Ki-67 > 14%
|
Total
|
ER+PgR+
|
365
|
301
|
666
|
ER+PgR+
|
49
|
123
|
172
|
ER+PgR−
|
26
|
40
|
66
|
ER+PgR−
|
9
|
29
|
38
|
ER−PgR+
|
6
|
5
|
11
|
ER−PgR+
|
0
|
0
|
0
|
Total
|
397
|
346
|
743
|
Total
|
58
|
152
|
210
|
Χ2(p)
|
5.73 (0.0167)
|
Χ2 (p)
|
0.36 (0.5489)
|
Distribution of ductal breast cancer patients according to their age and other features
|
Age of Luminal A patients
|
ER+PgR+
|
ER+PgR−
|
ER−PgR+
|
Age of HER2 patients
|
Ki-67 < =14%
|
Ki-67 > 14%
|
Total
|
<55
|
99
|
5
|
4
|
<55
|
3
|
38
|
41
|
>54
|
266
|
21
|
2
|
>54
|
16
|
78
|
94
|
Total
|
365
|
26
|
6
|
Total
|
19
|
116
|
135
|
Χ2(p)
|
0.77 (0.3789)
| |
Χ2 (p)
|
2.22 (0.1360)
| |
Age of Luminal B1 patients
|
ER+PgR+
|
ER+PgR−
|
ER−PgR+
|
Age of triple-negative patients
|
Ki-67 < =14%
|
Ki-67 > 14%
|
Total
|
<55
|
103
|
6
|
1
|
<55
|
7
|
68
|
75
|
>54
|
198
|
34
|
4
|
>54
|
14
|
71
|
85
|
Total
|
301
|
40
|
5
|
Total
|
21
|
139
|
160
|
Χ2(p)
|
6.00 (0.0143)
| |
Χ2 (p)
|
1.78 (0.1822)
| |
Age of Luminal B2 patients
|
ER+PgR+
|
ER+PgR−
|
ER−PgR+
|
Age of patients
|
triple-negative
|
HER2
|
Total
|
<55
|
65
|
4
|
0
|
<55
|
75
|
41
|
116
|
>54
|
107
|
34
|
0
|
>54
|
85
|
94
|
179
|
Total
|
172
|
38
|
0
|
Total
|
160
|
135
|
295
|
Χ2(p)
|
10.49 (0.0012)
| |
Χ2 (p)
|
8.36 (0.0038)
| |